Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation - a phase I study (MISOT-I). - University of Regensburg Publication Server

URN to cite this document:: urn:nbn:de:bvb:355-epub-218975
DOI to cite this document:: 10.5283/epub.21897

Popp, Felix C. ; Fillenberg, Barbara ; Eggenhofer, Elke ; Renner, Philipp ; Dillmann, Johannes ; Benseler, Volker ; Schnitzbauer, Andreas A. ; Hutchinson, James ; Deans, Robert ; Ladenheim, Deborah ; Graveen, Cheryl A. ; Zeman, Florian ; Koller, Michael ; Hoogduijn, Martin J. ; Geissler, Edward K. ; Schlitt, Hans J. ; Dahlke, Marc H.

Preview

License: Creative Commons: Attribution 3.0
PDF - Published Version
(880kB)

Date of publication of this fulltext: 09 Sep 2011 09:46

Alternative links to fulltext:Pubmed DOI

Details

Preview

Export bibliographical data

Abstract

BACKGROUND: Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to be reduced. In the current protocol, we propose to complement immunosuppressive pharmacotherapy ...